Aspirin resistance is not a common biochemical phenotype explained by unblocked cyclooxygenase-1 activity

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 1, 2003, Pages 196-197

  Hillarp, A ^a   Lethagen, S ^a   Mattiasson, I ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; CYCLOOXYGENASE 1; ISOENZYME; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN;

ADULT; BIOSYNTHESIS; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HUMAN; LETTER; METABOLISM; MIDDLE AGED; PHENOTYPE; PHYSIOLOGY; THROMBOCYTE AGGREGATION;

ADENOSINE TRIPHOSPHATE; ADULT; ASPIRIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DRUG RESISTANCE; FEMALE; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; MIDDLE AGED; PHENOTYPE; PLATELET AGGREGATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0141595869     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00012.x     Document Type: Letter

References (10)

1. Grotemeyer K-H. Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991; 63: 587-93.
2. Grotemeyer K-H, ScharafinskiHW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
3. Helgason CM, Hoff JA, Kondos GT, Brace LD. Platelet aggregation in patients with atrial fibrillation taking aspirin or warfarin. Stroke 1993; 24: 1458-61.
4. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994; 25: 2331-6.
5. Pappas JM, Westengard JC, Bull BS. Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Laboratory Med 1994; 118: 801-4.
6. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5.
7. Eikelboom JW, Hirsch J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-5.
8. Shimokawa T, Smith WL. Prostaglandin endoperoxide synthase: the aspirin acetylation region. J Biol Chem 1992; 267: 12387-92.
9. Feinman RD, Lubowsky J, Charo I, Zabinshy J. The lumi-aggregometer: a new instrument for simultaneous measurement of aggregation and secretion. J Laboratory Clin Med 1977; 90: 125-9.
10. Podczasy JJ, Lee J, Vucenik I. Evaluation of whole-blood lumiaggregation. Clin Appl Thromb-Hem 1997; 3: 190-5.